Found 3 matches for
A new exhibition tells the story of Oxford’s role in the fight against typhoid, from pioneering efforts to eliminate typhoid in the era of Lewis Carroll’s Alice in Wonderland to game-changing present-day vaccine trials
Awards & Appointments Neuromuscular Diseases
9 December 2020
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
Awards & Appointments Neuromuscular Diseases Public Engagement
25 August 2020
The awardees for the second round of the University of Oxford’s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.
Neuromuscular Diseases Publication
12 August 2020
Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.